Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort.

Authors: Busch, Robert; Han, MeiLan K; Bowler, Russell P; Dransfield, Mark T; Wells, J Michael; Regan, Elizabeth A; Hersh, Craig P; COPDGene Investigators

Published In BMC Pulm Med, (2016 Feb 10)

Abstract: BACKGROUND: Despite inhaled medications that decrease exacerbation risk, some COPD patients experience frequent exacerbations. We determined prospective risk factors for exacerbations among subjects in the COPDGene Study taking inhaled medications. METHODS: 2113 COPD subjects were categorized into four medication use patterns: triple therapy with tiotropium (TIO) plus long-acting beta-agonist/inhaled-corticosteroid (ICS ± LABA), tiotropium alone, ICS ± LABA, and short-acting bronchodilators. Self-reported exacerbations were recorded in telephone and web-based longitudinal follow-up surveys. Associations with exacerbations were determined within each medication group using four separate logistic regression models. A head-to-head analysis compared exacerbation risk among subjects using tiotropium vs. ICS ± LABA. RESULTS: In separate logistic regression models, the presence of gastroesophageal reflux, female gender, and higher scores on the St. George's Respiratory Questionnaire were significant predictors of exacerbator status within multiple medication groups (reflux: OR 1.62-2.75; female gender: OR 1.53 - OR 1.90; SGRQ: OR 1.02-1.03). Subjects taking either ICS ± LABA or tiotropium had similar baseline characteristics, allowing comparison between these two groups. In the head-to-head comparison, tiotropium users showed a trend towards lower rates of exacerbations (OR = 0.69 [95 % CI 0.45, 1.06], p = 0.09) compared with ICS ± LABA users, especially in subjects without comorbid asthma (OR = 0.56 [95% CI 0.31, 1.00], p = 0.05). CONCLUSIONS: Each common COPD medication usage group showed unique risk factor patterns associated with increased risk of exacerbations, which may help clinicians identify subjects at risk. Compared to similar subjects using ICS ± LABA, those taking tiotropium showed a trend towards reduced exacerbation risk, especially in subjects without asthma. TRIAL REGISTRATION: ClinicalTrials.gov NCT00608764, first received 1/28/2008.

PubMed ID: 26861867 Exiting the NIEHS site

MeSH Terms: Administration, Inhalation; Adrenal Cortex Hormones/therapeutic use*; Adrenergic beta-Agonists/therapeutic use*; Aged; Asthma/epidemiology; Bronchodilator Agents/therapeutic use*; Cohort Studies; Comorbidity; Disease Progression*; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroesophageal Reflux/epidemiology; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive/drug therapy*; Pulmonary Disease, Chronic Obstructive/epidemiology; Risk Factors; Sex Factors; Tiotropium Bromide/therapeutic use*

Back
to Top